| scholarly article | Q13442814 |
| P2093 | author name string | Michael A Rogawski | |
| Henrik Klitgaard | |||
| Rafal M Kaminski | |||
| P2860 | cites work | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 |
| Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI) | Q26825591 | ||
| Cyclooxygenase-2 in epilepsy. | Q26827095 | ||
| Mitochondrial involvement and oxidative stress in temporal lobe epilepsy | Q26865259 | ||
| Anti-epileptogenic clinical trial designs in epilepsy: issues and options | Q27027689 | ||
| Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury | Q27319659 | ||
| A systems level, functional genomics analysis of chronic epilepsy | Q27335505 | ||
| Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma | Q27693823 | ||
| The mechanisms of action of PPARs | Q28216953 | ||
| Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring | Q28243804 | ||
| Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. | Q28281249 | ||
| Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties | Q28302788 | ||
| Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection | Q28396785 | ||
| The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy | Q28579751 | ||
| Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent | Q28584148 | ||
| Growing roles for the mTOR pathway | Q29616212 | ||
| Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen | Q29616224 | ||
| Epilepsy biomarkers. | Q30411290 | ||
| A role for leukocyte-endothelial adhesion mechanisms in epilepsy | Q30488791 | ||
| Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy | Q30496223 | ||
| Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. | Q30497503 | ||
| Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice | Q30500480 | ||
| Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome | Q30537599 | ||
| Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy | Q30542932 | ||
| Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies | Q30576762 | ||
| Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy | Q30622871 | ||
| Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. | Q33269936 | ||
| Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy | Q34031703 | ||
| Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. | Q34155940 | ||
| Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation | Q34226575 | ||
| Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments | Q34282066 | ||
| Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus | Q48484426 | ||
| Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice | Q48485327 | ||
| Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. | Q48722531 | ||
| The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus | Q48901148 | ||
| Atorvastatin treatment during epileptogenesis in a rat model for temporal lobe epilepsy | Q49090389 | ||
| Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. | Q52051559 | ||
| Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. | Q52198955 | ||
| Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. | Q52609125 | ||
| Levetiracetam may favorably affect seizure outcome after temporal lobectomy. | Q53168417 | ||
| Vascular endothelial growth factor up-regulation in the mouse hippocampus and its role in the control of epileptiform activity. | Q54394455 | ||
| Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway | Q59344888 | ||
| The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators | Q61415555 | ||
| Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy | Q61676480 | ||
| Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage | Q71128803 | ||
| Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy | Q74138296 | ||
| Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis | Q75351318 | ||
| Topiramate promotes neurological recovery in a new model of traumatic brain injury in rats | Q83876444 | ||
| Neuroprotective effects of recombinant human erythropoietin in the developing brain of rat after lithium-pilocarpine induced status epilepticus | Q84159649 | ||
| Levetiracetam: the first SV2A ligand for the treatment of epilepsy | Q86363817 | ||
| Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86 | Q86910950 | ||
| Erythropoietin pretreatment suppresses seizures and prevents the increase in inflammatory mediators during pentylenetetrazole-induced generalized seizures | Q87047234 | ||
| Lovastatin modulates glycogen synthase kinase-3β pathway and inhibits mossy fiber sprouting after pilocarpine-induced status epilepticus | Q34325797 | ||
| VEGF receptor-2 (Flk-1) overexpression in mice counteracts focal epileptic seizures | Q34342111 | ||
| The mechanism of neuroprotection by topiramate in an animal model of epilepsy. | Q34372245 | ||
| Prevention or Modification of Epileptogenesis after Brain Insults: Experimental Approaches and Translational Research | Q34458158 | ||
| Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. | Q34482995 | ||
| Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association | Q34576407 | ||
| Statins: mechanism of action and effects. | Q34687736 | ||
| Early treatment suppresses the development of spike-wave epilepsy in a rat model | Q34723299 | ||
| The role of catecholamines in seizure susceptibility: new results using genetically engineered mice | Q34734993 | ||
| Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy | Q34778218 | ||
| Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis | Q35028378 | ||
| Promise of resveratrol for easing status epilepticus and epilepsy | Q35097960 | ||
| How do statins control neuroinflammation? | Q35547770 | ||
| The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. | Q35824087 | ||
| Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword | Q35834542 | ||
| Peroxisome proliferator-activated receptors γ/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. | Q36241486 | ||
| The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate | Q36326299 | ||
| Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus | Q36402077 | ||
| Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin | Q36574727 | ||
| Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models | Q36590070 | ||
| Age-dependent effects of topiramate on the acquisition and the retention of rapid kindling. | Q36647742 | ||
| Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation | Q36653830 | ||
| Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. | Q36690609 | ||
| Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. | Q36703584 | ||
| Mammalian target of rapamycin: master regulator of cell growth in the nervous system | Q36822152 | ||
| Development of new antiepileptic drugs: challenges, incentives, and recent advances | Q36913503 | ||
| Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy | Q37161340 | ||
| Finding a better drug for epilepsy: antiepileptogenesis targets. | Q37232240 | ||
| Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death | Q37243450 | ||
| BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. | Q37306648 | ||
| Bumetanide inhibits rapid kindling in neonatal rats | Q37320851 | ||
| Preventing and treating posttraumatic seizures: the human experience | Q37383515 | ||
| Posttraumatic epilepsy: the challenge of translating discoveries in the laboratory to pathways to a cure | Q37383526 | ||
| Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model | Q37399998 | ||
| Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias | Q43117316 | ||
| Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy | Q43240417 | ||
| Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis | Q43245957 | ||
| Effect of topiramate following recurrent and prolonged seizures during early development | Q44193568 | ||
| The PPARγ agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF/TrkB signaling following pilocarpine-induced status epilepticus | Q44196643 | ||
| The N-methyl-D-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures | Q44284970 | ||
| Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model | Q44308125 | ||
| Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis | Q44508301 | ||
| Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. | Q44527858 | ||
| The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy | Q44572950 | ||
| Interleukin-1β Enhances NMDA Receptor-Mediated Intracellular Calcium Increase through Activation of the Src Family of Kinases | Q44595357 | ||
| Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy | Q44616602 | ||
| Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy | Q44639225 | ||
| The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats | Q44729812 | ||
| Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model | Q44829751 | ||
| Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing p | Q44880525 | ||
| Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats | Q44912317 | ||
| Atipamezole, an alpha(2)-adrenoceptor antagonist, has disease modifying effects on epileptogenesis in rats | Q45080312 | ||
| Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy | Q45284051 | ||
| Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. | Q45987760 | ||
| Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. | Q46082573 | ||
| Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects. | Q46092465 | ||
| Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats | Q46121091 | ||
| Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy | Q46137073 | ||
| Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats | Q46308837 | ||
| Effect of topiramate on cognitive function and single units from hippocampal place cells following status epilepticus | Q46311109 | ||
| Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery | Q46412337 | ||
| Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats | Q46414611 | ||
| Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production | Q46480418 | ||
| Erythropoietin reduces epileptogenic processes following status epilepticus | Q46596388 | ||
| Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). | Q46629490 | ||
| Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model | Q46657489 | ||
| Management of epilepsy in tuberous sclerosis complex. | Q46697537 | ||
| Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. | Q46729231 | ||
| Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy | Q46954553 | ||
| Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. | Q46964954 | ||
| Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy | Q47795001 | ||
| Effect of levetiracetam on visual-spatial memory following status epilepticus | Q47847677 | ||
| Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats | Q48129101 | ||
| Topiramate reduces neuronal injury after experimental status epilepticus | Q48144553 | ||
| Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy | Q48154139 | ||
| The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures | Q48178824 | ||
| Leukocyte trafficking mechanisms in epilepsy | Q48193828 | ||
| Amelioration of water maze performance deficits by topiramate applied during pilocarpine-induced status epilepticus is negatively dose-dependent | Q48379272 | ||
| Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model | Q48384403 | ||
| Antiepileptic effects of topiramate on amygdaloid kindling in rats | Q48406834 | ||
| Comparison of valproate and phenobarbital treatment after status epilepticus in rats | Q48425188 | ||
| The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy | Q48431895 | ||
| Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element | Q48432157 | ||
| Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy | Q48455854 | ||
| Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury | Q48466104 | ||
| Convection-enhanced delivery in the treatment of epilepsy | Q37426998 | ||
| Issues related to development of new antiseizure treatments | Q37626397 | ||
| Therapeutic approaches to epileptogenesis--hope on the horizon | Q37771378 | ||
| Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier | Q37819809 | ||
| Erythropoietin, erythropoiesis and beyond | Q37904170 | ||
| Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations | Q37947981 | ||
| Inflammation and epilepsy. | Q38039590 | ||
| Mechanisms of action of antiseizure drugs | Q38039637 | ||
| Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. | Q38043469 | ||
| Cerebrovascular remodeling and epilepsy | Q38052687 | ||
| Why and how to target angiogenesis in focal epilepsies | Q38058377 | ||
| From resveratrol to its derivatives: new sources of natural antioxidant | Q38064939 | ||
| Glia and epilepsy: excitability and inflammation | Q38072496 | ||
| Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery | Q38088316 | ||
| Toward clinical application of the Keap1-Nrf2 pathway | Q38105775 | ||
| Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis | Q38127463 | ||
| New avenues for anti-epileptic drug discovery and development | Q38139837 | ||
| Anti-epileptogenesis: Electrophysiology, diffusion tensor imaging and behavior in a genetic absence model. | Q38262225 | ||
| Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy | Q39646371 | ||
| Statin use and risk of epilepsy: a nested case-control study | Q39824263 | ||
| Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. | Q40460866 | ||
| VEGF and seizures: cross-talk between endothelial and neuronal environments | Q41772480 | ||
| IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients | Q42482233 | ||
| Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats | Q42497528 | ||
| Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus | Q42505506 | ||
| Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling | Q42654751 | ||
| Lack of resveratrol neuroprotection in developing rats treated with kainic acid | Q42714225 | ||
| Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. | Q42754610 | ||
| Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation | Q42811953 | ||
| Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy | Q42965558 | ||
| Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus | Q42989674 | ||
| Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy | Q43007324 | ||
| The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy | Q43114554 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 385-400 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments | |
| P478 | volume | 11 |
| Q89208077 | Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy |
| Q47954974 | Anticonvulsant Effect of Swertiamarin Against Pilocarpine-Induced Seizures in Adult Male Mice |
| Q49038495 | Anticonvulsant effect of a ghrelin receptor agonist in 6Hz corneally kindled mice |
| Q38752407 | Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment |
| Q47653416 | Commonalities in epileptogenic processes from different acute brain insults: Do they translate? |
| Q35205988 | Comprehensive identification of essential pathways and transcription factors related to epilepsy by gene set enrichment analysis on microarray datasets |
| Q27342573 | Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models |
| Q64927994 | Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting. |
| Q38450069 | Disease modification in epilepsy: from animal models to clinical applications |
| Q37707520 | EphA4 may contribute to microvessel remodeling in the hippocampal CA1 and CA3 areas in a mouse model of temporal lobe epilepsy. |
| Q34445004 | Epilepsy management: newer agents, unmet needs, and future treatment strategies. |
| Q38754189 | Exploring the latest avenues for antiepileptic drug discovery and development |
| Q38707729 | Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model |
| Q34914125 | IL-1β and IL-18: inflammatory markers or mediators of hypertension? |
| Q28272457 | Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet |
| Q92044171 | Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues |
| Q47614751 | Modulation of brain glutamate dehydrogenase as a tool for controlling seizures |
| Q93113544 | N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug |
| Q42336430 | Novel concepts in epileptogenesis and its prevention |
| Q38667129 | Prevention of epilepsy: Should we be avoiding clinical trials? |
| Q30836611 | RNA sequencing of synaptic and cytoplasmic Upf1-bound transcripts supports contribution of nonsense-mediated decay to epileptogenesis. |
| Q60473670 | Studies on the anticonvulsant activity and influence on GABA-ergic neurotransmission of 1,2,4-triazole-3-thione- based compounds |
| Q28068507 | Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond |
| Q36314084 | Synthesis and Anticonvulsant Properties of New 3,3-Diphenyl-2,5-dioxo-pyrrolidin-1-yl-acetamides and 3,3-Diphenyl-propionamides. |
| Q47633070 | Synthesis and Determination of Lipophilicity, Anticonvulsant Activity, and Preliminary Safety of 3-Substituted and 3-Unsubstituted N-[(4-Arylpiperazin-1-yl)alkyl]pyrrolidine-2,5-dione Derivatives. |
| Q99711400 | The Concept of an Epilepsy Brain Bank |
| Q64250611 | The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure |
| Q48414222 | The Ephrin-A5/EphA4 Interaction Modulates Neurogenesis and Angiogenesis by the p-Akt and p-ERK Pathways in a Mouse Model of TLE. |
| Q36564626 | Value of Functionalized Superparamagnetic Iron Oxide Nanoparticles in the Diagnosis and Treatment of Acute Temporal Lobe Epilepsy on MRI. |
Search more.